

Diabetic Retinopathy Guideline Committee Meeting 8

Date: 12th January 2023
Location: Virtual Meeting via Zoom
Minutes: Draft

Committee members present:	
Mike Burdon (Chair)	Present for all items
John Anderson	Present for items 5-8
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Christiana Dinah	Present for all items
Noemi Lois	Present for all items
Diva Shah	Present for all items
Lloyd Thomas	Present for all items
Bernadette Warren	Present for all items
Becky Wei Luo	Present for all items

In attendance:		
Nicola Cunliffe	Project Manager, Guideline Development Team	Present for all items
Clare Dadswell	Senior Technical Analyst, Guideline Development Team	Present for all items
Jacqueline Durkin	Administrator, Guideline Development Team	Present for item 1
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Hugh McGuire	Technical Adviser – NICE International	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Ahmed Yousef	Technical Analyst, Guideline Development Team	Present for all items

Apologies:	
Catrina Charlton	Guideline Commissioning Manager, NICE
Astrid Aregui	Senior Medical Editor, NICE
Louis Savage	Committee Member
Magdalena Watras	Medicines Lead, NICE

1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the 8th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. The declarations are as follows:

Noemi Lois declared that she is CI for NIHR-HTA funded UK multicentric DIAMONDS, RCT on laser (standard laser versus subthreshold micropulse laser) and EMERALD a diagnostic accuracy study evaluating models of care - both included cost-effectiveness analysis. EMERALD and DIAMONDS are publicly funded (NIHR).

The Chair advised that this and the interests previously declared did not prevent the attendees from fully participating in the meeting.

2. Laser and anti-VEGF for PDR (RQ5)

- **Model approach presentation**
- **Model results and discussion**
- **Revisit the recommendations**

The Chair introduced Kirsty Luckham (KL), who gave a presentation on the model approach for laser and anti-VEGF for PDR (RQ5). KL reviewed the model results and led a discussion with the committee.

KL revisited the recommendations for (RQ5). The committee had the opportunity to give feedback and ask questions.

3. RQ5 discussions continued

The committee continued the discussions for laser and anti-VEGF for PDR (RQ5).

4. Macular Oedema treatments NMA (RQ7)

- **Potential lay member presentation**
- **NMA**

The Chair introduced Ahmed Yosef (AY), who gave a presentation on the potential lay member for Macular Oedema treatments NMA (RQ7) and led a discussion with the committee on NMA.

The committee had the opportunity to engage and ask questions.

5. RQ7

- **NMA continued**
- **Health economic model results**
- **Committee discussion**

AY and KL continued the discussion about NMA and reviewed the health economic model results for

(RQ7) with the committee.

The committee had the opportunity to give feedback and ask questions.

6. RQ7

- **Discussions continued**

The committee continued the discussion for (RQ7).

7. AOB, summary and next steps

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.